$Aldeyra Therapeutics(ALDX.US)$Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease expected to submit to FDA in 2H
$Aldeyra Therapeutics(ALDX.US)$ NEWS Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease Positive Enrollment of the first patient in the Phase 3 clinical trial for reproxalap indicates progress in Aldeyra Therapeutics' efforts to address dry eye disease. Potential resubmission of the NDA for reproxalap in the second half of 2024 demonstrates the company's commitment to advancing in...
Aldeyra Therapeutics股票討論區
NEWS
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Positive
Enrollment of the first patient in the Phase 3 clinical trial for reproxalap indicates progress in Aldeyra Therapeutics' efforts to address dry eye disease.
Potential resubmission of the NDA for reproxalap in the second half of 2024 demonstrates the company's commitment to advancing in...
格拉巴律師事務所正在代表阿德伊拉治療有限公司(納斯達克:ALDX)股東調查索賠。調查涉及 Aldeyra 部分人員是否違反對該公司的信託責任。
Aldeyra 現有股東,自以來一直持有阿德耶拉股份 在一月之前...
• 因此,阿布維(阿布夫) 是 支付不可退款 5 萬美元 期權延長費用。
• 原有的期權協議是 於十月下旬簽署.
• 阿比維 (阿布夫) 現在可以在... 後的第 10 個工作日 (a) 之前行使其期權
暫無評論